PetMed Express (PETS) Q2 2027 earnings summary

Executive summary

• Q2 FY2027 net sales fell 19.4% YoY to $35.770M; net loss narrowed to $6.434M from $8.520M, while Adjusted EBITDA loss widened to $3.643M from $2.316M.

• Operations were described as stabilized; priorities include reshaping the direct-to-consumer pharmacy business and returning to profitable growth.

Financial highlights

• Q2 gross profit fell to $9.803M from $12.415M; operating loss was $6.419M versus $8.380M.

• Q2 operating expenses declined to $16.222M from $20.795M; G&A fell 15.6% to $12.0M and advertising fell 52.3% to $2.1M.

• H1 net sales were $76.785M versus $95.544M; net loss was $12.579M versus $42.672M, including a $27.258M prior-year impairment charge.

• H1 Adjusted EBITDA loss was $7.091M versus $5.012M.

Outlook and guidance

• Priorities include clearer brand positioning, more efficient marketing, simpler online checkout, stronger retention, and a focused product assortment.

• Management cited a credible path to profitability and then growth, while noting customer relationship rebuilding is a multi-year effort; no numerical financial outlook was stated.

• Management said cost and marketing actions alleviate substantial doubt about the ability to continue as a going concern over the next 12 months; sales remain difficult to predict.